Share this Article
Singapore Med J 2014; 55(7): 353-357; http://dx.doi.org/10.11622/smedj.2014085
Male osteoporosis: clinical approach and management in family practice
Goh LH, How CH, Lau TC
Correspondence: Dr Goh Lay Hoon, goh.lay.hoon@singhealth.com.sg
ABSTRACT
In Singapore, male osteoporosis is gaining greater importance due to our ageing population. Family physicians should screen for osteoporosis in elderly men and men with risk factors or secondary causes for the condition. A bone mineral density (BMD) test is used for diagnosis. FRAX® can be used to predict the absolute ten-year fracture risk. Management includes reduction of risk factors or secondary causes, fall prevention, appropriate physical activity and a diet adequate in calcium and vitamin D. Referrals to specialists for evaluation and therapy can be considered, particularly for younger men with more severe disease. Current first-line drug treatment includes bisphosphonates and teriparatide. Testosterone increases BMD of the spine, but data on fracture risk reduction is unavailable. Public and physician education with the involvement of health authorities can create greater awareness of this silent condition, which can lead to complications, morbidity and death, if left untreated.
Keywords: bone mineral density, family physicians, fracture, FRAX, male osteoporosis
Singapore Med J 2014; 55(7): 353-357; http://dx.doi.org/10.11622/smedj.2014085
REFERENCES
| 1. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int 2001; 12:699-705. http://dx.doi.org/10.1007/s001980170070 | ||||
| 2. Chan SP, Teo CC, Ng SA, et al. Validation of various osteoporosis risk indices in elderly Chinese females in Singapore. Osteoporos Int 2006; 17: 1182-8. http://dx.doi.org/10.1007/s00198-005-0051-4 | ||||
| 3. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581-9. http://dx.doi.org/10.1007/s00198-004-1780-5 | ||||
| 4. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90:107-10. http://dx.doi.org/10.1016/0002-9343(91)90512-V | ||||
| 5. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997; 7:1-6. http://dx.doi.org/10.1007/BF01623453 | ||||
| 6. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-94. http://dx.doi.org/10.1359/JBMR.050304 | ||||
| 7. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-9. http://dx.doi.org/10.1136/bmj.312.7041.1254 | ||||
| 8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129. PMid:7941614 | ||||
| 9. Melton LJ 3rd, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res 1998; 13:1915-23. http://dx.doi.org/10.1359/jbmr.1998.13.12.1915 | ||||
| 10. Johnell O, Kanis JA, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726-33. http://dx.doi.org/10.1007/s00198-006-0172-4 | ||||
| 11. Koh LK, Saw SM, Lee JJ, et al. Hip fracture incidence rates in Singapore 1991-1998. Osteoporos Int 2001; 12:311-8. http://dx.doi.org/10.1007/s001980170121 | ||||
| 12. Wong PC. Fracture epidemiology in a mixed southeastern Asian community (Singapore). Clin Orthop Relat Res 1966; 45:55-61. http://dx.doi.org/10.1097/00003086-196600450-00007 | ||||
| 13. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375-82. http://dx.doi.org/10.1016/j.bone.2004.03.024 | ||||
| 14. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297:387-94. http://dx.doi.org/10.1001/jama.297.4.387 | ||||
| 15. Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298:2381-8. http://dx.doi.org/10.1001/jama.298.20.2381 | ||||
| 16. Jiang HX, Majumdar SR, Dick DA, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20:494-500. http://dx.doi.org/10.1359/JBMR.041133 | ||||
| 17. Lee AY, Chua BS, Howe TS. One-year outcome of hip fracture patients admitted to a Singapore hospital: quality of life post-treatment. Singapore Med J 2007; 48:996-9. PMid:17975688 | ||||
| 18. Di Monaco M, Castiglioni C, Vallero F, Di Monaco R, Tappero R. Men recover ability to function less than women do: an observational study of 1094 subjects after hip fracture. Am J Phys Med Rehabil 2012; 91:309-15. http://dx.doi.org/10.1097/PHM.0b013e3182466162 | ||||
| 19. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton LJ 3rd. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551-5. http://dx.doi.org/10.1016/8756-3282(94)90280-1 | ||||
| 20. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95. PMid:11176917 | ||||
| 21. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6:39. http://dx.doi.org/10.1186/1471-2474-6-39 | ||||
| 22. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009; 29:311-5. http://dx.doi.org/10.1007/s00296-008-0689-2 | ||||
| 23. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-10. http://dx.doi.org/10.1056/NEJM200008313430902 | ||||
| 24. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24:719-25. http://dx.doi.org/10.1359/jbmr.081214 | ||||
| 25. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010; 25:2239-50. http://dx.doi.org/10.1002/jbmr.119 | ||||
| 26. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165:1743-8. http://dx.doi.org/10.1001/archinte.165.15.1743 | ||||
| 27. Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68:243-53. http://dx.doi.org/10.1016/j.joms.2009.03.050 | ||||
| 28. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28:1729-37. http://dx.doi.org/10.1002/jbmr.1893 | ||||
| 29. Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86:957-64. http://dx.doi.org/10.1210/jcem.86.3.7366 | ||||
| 30. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85:3069-76. PMid:10999788 | ||||
| 31. Kaufman JM, Orwoll E, Goemaere S, et al.Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16:510-6. http://dx.doi.org/10.1007/s00198-004-1713-3 | ||||
| 32. Tracz MJ, Sideras K, Bolo-a ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91:2011-6. http://dx.doi.org/10.1210/jc.2006-0036 | ||||
| 33. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216-26. http://dx.doi.org/10.1056/NEJMoa035725 | ||||